Summit Therapeutics Inc. Net Fee Amt
Summit Therapeutics Inc. (SMMT) had Net Fee Amt of $52.48 thousand as of 2026-07-21, per its 424B5 filed 2026-07-23.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-23
- 2026-07-21: Net Fee Amt $52.48K.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-21 | $52.48K 424B5 · filed 2026-07-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |